02
Sep
Tyrosine Kinase Inhibitor Drugs Side Effects. This profiling also implicates activity at particular off-target kinases in drug side effects. Sorafenib is a small molecule inhibitor of many tyrosine kinase receptors such as VEGFR-2. We propose that TKI approved for human use and widely available can be rapidly deployed as specific target-based therapy for COVID-19. Patients receiving a TKI should be monitored for increasing side effects anemia neutropenia folliculitis skin rash edema nausea vomiting and diarrhea if an inhibitor of CYP3A4 is coadministered.
Sorafenib is a small molecule inhibitor of many tyrosine kinase receptors such as VEGFR-2. Examples of TKIs include. There is increasing evidence that patients whose disease is controlled by TKIs will have greater impact on their quality of life from comorbidities or drug adverse events than from the disease itself. Tyrosine kinases help to send growth signals in cells so blocking them stops the cell growing and dividing. Cancer growth blockers can block one type of tyrosine kinase or more than one type. TKIs are typically used as anticancer drugs but also for other diseases such as idiopathic pulmonary.
The Effect of Enzyme Inducers on TKIs Rifampin is an inducer of most CYP450 enzymes and has been shown to reduce the AUC of most TKIs.
Cutaneous Adverse Effects of Small-Molecule Tyrosine Kinase Inhibitors. Sorafenib is a small molecule inhibitor of many tyrosine kinase receptors such as VEGFR-2. Patients receiving a TKI should be monitored for increasing side effects anemia neutropenia folliculitis skin rash edema nausea vomiting and diarrhea if an inhibitor of CYP3A4 is coadministered. Cutaneous Adverse Effects of Small-Molecule Tyrosine Kinase Inhibitors. Competing Interest Statement. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.